← Back to Search

(18F)-FEPPA PET/MRI Imaging for Frontotemporal Dementia

N/A

Recruiting

Research Sponsored by London Health Sciences Centre Research Institute and Lawson Research Institute of St. Joseph's

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Subject is not pregnant, lactating, or of childbearing potential (i.e. women must be two years post-menopausal, surgically sterile or practicing an effective form of family planning

Patients diagnosed with a probable Frontotemporal Dementia or neurologically healthy control participants with no history of neurological problems

Must not have

Any significant neurologic disease other than suspected Frontotemporal Dementia that would better account for symptoms (i.e. frontal lobe stroke)

Exclusion Criteria for controls undergoing arterial line placement: Absent pulse, Thromboangiitis obliterans (Buerger disease), Burns over the cannulation site, Inadequate circulation to the extremity, Raynaud syndrome, Anticoagulation therapy, Atherosclerosis of upper extremity vessels, Coagulopathy, inadequate collateral flow, Infection at the cannulation site, Previous surgery in the area, Synthetic vascular graft

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

No Placebo-Only Group

Summary

This trial will use hybrid PET/MRI imaging to study neuroinflammation in frontotemporal dementia patients and its relationship to cerebral perfusion.

Who is the study for?

This trial is for individuals diagnosed with probable Frontotemporal Dementia or healthy controls without neurological issues. Participants need a study partner, must be in good health not affecting the study, and women should not be pregnant or of childbearing potential unless properly managed. Exclusions include significant systemic illness, certain medical conditions that affect MRI safety, other major neurologic diseases besides FTD, recent psychiatric disorders, and those exceeding radiation exposure limits.

What is being tested?

(18F)-FEPPA PET/MRI imaging is being tested to assess neuroinflammation's role in Frontotemporal Dementia (FTD). The trial involves cognitive assessments and advanced imaging techniques to explore the relationship between brain inflammation, blood flow, and brain structure in patients with different subtypes of FTD.

What are the potential side effects?

While the document does not specify side effects related to FEPPA directly since it's an imaging agent used for PET scans; generally such procedures may involve risks from radiation exposure although within safe limits set by health regulations. There might also be discomfort associated with positioning during scanning.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am not pregnant, breastfeeding, and cannot become pregnant.

Select...

I have been diagnosed with probable Frontotemporal Dementia or I am neurologically healthy with no history of neurological issues.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

My symptoms are not due to a major neurological condition other than possible Frontotemporal Dementia.

Select...

I do not have conditions like absent pulse, specific vessel diseases, burns, poor circulation, or infections that would prevent arterial line placement.